Sorafenib in Dupuytren and Ledderhose Disease.

Joshua D Schoenfeld, Narasimhan P Agaram, Robert A Lefkowitz, Ciara M Kelly, John H Healey, Mrinal M Gounder

The oncologist 2022 Mar 11

filter terms:

Palmar and plantar fibromatosis are benign proliferative processes which present as a diffuse thickening or nodules of the hands and/or feet and may lead to flexion contractures, pain, and functional impairment known as Dupuytren and Ledderhose diseases, respectively. Current treatments are noncurative and associated with significant morbidity. Here, we report on the outcomes of 5 patients with advanced disease, no longer surgical candidates, treated with sorafenib. Sorafenib exhibited an expected safety profile. All 5 patients demonstrated objective responses as evaluated by a decrease in tumor size and/or tumor cellularity from baseline and all 5 patients reported subjective pain relief and/or functional improvement. Mechanistically, immunohistochemistry revealed patchy positivity for PDGFRβ, a known target of sorafenib. The outcomes of these 5 patients suggest the safety and efficacy of a relatively well-tolerated oral agent in the treatment of Dupuytren and Ledderhose diseases and suggest the need for future controlled studies. © The Author(s) 2022. Published by Oxford University Press.

Citation

Joshua D Schoenfeld, Narasimhan P Agaram, Robert A Lefkowitz, Ciara M Kelly, John H Healey, Mrinal M Gounder. Sorafenib in Dupuytren and Ledderhose Disease. The oncologist. 2022 Mar 11;27(3):e294-e296